Author

Yong Man Kim

Institution: NKGen Biotech Inc. (United States)

Observed institutions: Nkmax (South Korea), NKGen Biotech Inc. (United States)

ORCID: 0000-0002-1851-6959

Observed ORCID: 0000-0002-1851-6959

OpenAlex ID: A5071499791

Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial

2021 · Dalsan You, Myoung Jin Jang, et al. · Cytotherapy · 37

A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer

2021 · Eo Jin Kim, Yong-Hee Cho, et al. · Cancer Research and Treatment · 28

Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study

2025 · Clemente Humberto Zúñiga, Blanca Isaura Acosta, et al. · Alzheimer s Research & Therapy · 15

Two‐year efficacy of SNK01 plus pembrolizumab for non‐small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial

2022 · Hyung Jun Park, Yong Man Kim, et al. · Thoracic Cancer · 14

296 HER2-specific highly scalable CAR NK cell (anti-HER2-CAR SNK02) exhibits a significantly enhanced antitumor activity against HER2-expressing tumors as an off-the-shelf allogeneic immune cell therapy

2023 · Yong-hee Rhee, Hee-Sung Chae, et al. · Journal for ImmunoTherapy of Cancer · 2

Establishment of NOAEL for intracavernous injections of human bone marrow-derived mesenchymal stem cells in rats

2020 · Jong Keun Kim, Myoung Jin Jang, et al. · Korean journal of urology · 1

The safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: Preclinical mouse model and phase I/IIa clinical study.

2023 · Myeong Geun Choi, Gun Woo Son, et al. · Journal of Clinical Oncology

Works count: 7

Citation count: 97

H-index: 4

I10-index: 4